An Open-Label Study for Previously Treated Ataluren (PTC124) Patients With Nonsense Mutation Dystrophinopathy

Trial Profile

An Open-Label Study for Previously Treated Ataluren (PTC124) Patients With Nonsense Mutation Dystrophinopathy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs Ataluren (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions
  • Sponsors PTC Therapeutics
  • Most Recent Events

    • 08 Mar 2018 This trial has been completed in Sweden (end date: 2018-01-19)
    • 07 Mar 2018 This trial has been completed in Belgium and Germany (end date: 2018-01-19)
    • 16 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top